Nachrichten zur Exact Sciences Corp. Aktie

Exact Sciences (NASDAQ:EXAS) shareholders have endured a 31% loss from investing in the stock three years ago

While not a mind-blowing move, it is good to see that the Exact Sciences Corporation ( NASDAQ:EXAS ) share price…

Can This Beaten-Down Cathie Wood Stock Bounce Back?

An updated version of Exact Sciences key product just got regulatory approval. That could help the healthcare stock stage a…

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening

Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high…

Exact Sciences wins FDA approval for non-invasive colorectal cancer test

…

Is EXAS Stock a Smart Addition to Your Portfolio Right Now?

Exact Sciences is making solid headway in promoting Cologuard as the benchmark for care.…

Exact Sciences spikes ahead of data for blood-based cancer test

…

Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches

Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard…

Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study

Exact Sciences (EXAS) initiates the MCED Falcon Registry study, with Baylor Scott & White Health and Endeavor Health serving as…

Exact Sciences: Cost Optimization And Product Strength

…

Why You Should Add Exact Sciences (EXAS) to Your Portfolio

Exact Sciences (EXAS) progress with strategic priority and strong solvency bode well.…

Exact Sciences (EXAS) Q2 2024 Earnings Call Transcript

EXAS earnings call for the period ending June 30, 2024.…

Exact Sciences (EXAS) Q2 Loss Narrower Than Expected, Sales Beat

Exact Sciences (EXAS) second-quarter 2024 top-line results reflect robust revenues from the Screening and Precision Oncology segments.…

Exact Sciences: Still No Reason To Own

…

Exact Sciences (EXAS) Witnesses Rising Expenses, Competition

Exact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.…

Exact Sciences (EXAS) to Showcase Favorable Research Outcome

Exact Sciences (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening…

ASCO®: Exact Sciences bekräftigt mit mehreren Datenpräsentationen seine langfristige Vorreiterrolle in der Krebsfrüherkennung und bei der Verbesserung von Behandlungsergebnissen

MADISON, Wisconsin--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), ein führender Anbieter von Krebsfrüherkennungs- und Diagnosetests, wird auf der Jahrestagung der American…

Exact Sciences stock drops as Guardant Health test supported by FDA panel By Investing.com

Exact Sciences stock drops as Guardant Health test supported by FDA panel…

Exact Sciences (EXAS) Q1 2024 Earnings Call Transcript

EXAS earnings call for the period ending March 31, 2024.…

Exact Sciences Shares Drop 10% on Earnings Miss By Investing.com

Exact Sciences Shares Drop 10% on Earnings Miss…

Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?

Exact Sciences (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth,…

Exact Sciences names Aaron Bloomer as CFO

…

How This CEO Consumerized Cancer Diagnostics Into A $13B Enterprise

A decade ago, Exact Sciences launched Cologuard, impacting the fight against colorectal cancer. Its growth of 7000% is in part…

Exact Sciences EVP sells $140k in company stock By Investing.com

Exact Sciences EVP sells $140k in company stock…

Citi sees Exact Sciences shares climbing after rivals data disappoints By Investing.com

Citi sees Exact Sciences shares climbing after rivals data disappoints…

Exact Sciences (EXAS) Oncoguard Esophagus Test Looks Promising

Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.…

Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau

…

Exact Sciences (EXAS) BLUE-C Study Results Published in NEJM

Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.…

Cathie Wood Darling Could Pop On Its Next-Gen Colon Cancer Test

Exact Sciences is hoping to launch an next-generation version of Cologuard in 2025.…

5 Small Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…

Exact Sciences (EXAS) Q4 2023 Earnings Call Transcript

EXAS earnings call for the period ending December 31, 2023.…

Exact Sciences (EXAS) Q4 Loss Narrows, Revenues Rise Y/Y

Robust revenues from Exact Sciences (EXAS) Screening and Precision Oncology segments contribute to the fourth-quarter top line.…

Exact Sciences (EXAS) to Post Q4 Earnings: Whats in Store?

Exact Sciences (EXAS) revenues in the fourth quarter of 2023 are likely to have been driven by its flagship cancer…

Top 5 Life Science ETFs

Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the…

Exact Sciences reports preliminary Q4 results; CFO to step down

…

Exact Sciences projects 17% Q4 revenue growth By Investing.com

Exact Sciences projects 17% Q4 revenue growth…

Exact Sciences (EXAS) Solid Cologuard Sales, Innovation Aid

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.…

Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences? @themotleyfool #stocks $EXAS $VRTX $CRSP

Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy…

Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?

Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy…

Heres Why You Should Retain Exact Sciences (EXAS) Stock Now

Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.…

Exact Sciences (EXAS) Up 35.4% YTD: Will the Rally Continue?

Investors are optimistic about Exact Sciences (EXAS), driven by growth in Screening and Precision Oncology segments.…

Exact Sciences sues Geneoscopy for alleged patent infringement

…

Exact Sciences (EXAS) Q3 2023 Earnings Call Transcript

EXAS earnings call for the period ending September 30, 2023.…

Exact Sciences Looks Fairly Valued After Its Q3 Earnings Beat

…

Exact Sciences (EXAS) Q3 Earnings Beat, Gross Margin Rises

Exact Sciences (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption.…

How to Invest in Genetics (Updated 2023)

Genetics is the study of genes, their variations and hereditary characteristics, as well as how these traits are passed on…

KI nicht nur als Schlagwort nutzen: Auf diese drei KI-Aktien abseits von NASDAQ-Titel NVIDIA-Aktie setzt Cathie Wood

• Fast jeder Titel in ARKs Flaggschiffstrategie soll im Bereich der künstlichen Intelligenz engagiert sein• Wood setzt auf Unternehmen mit…

Heres Why You Should Retain Exact Sciences (EXAS) Stock Now

Investors remain optimistic about Exact Sciences (EXAS) due to its strategic prioritization and positive solvency.…

Exact Sciences upgraded at Piper Sandler on compelling entry point

…

Where Will Exact Sciences Be in 5 Years?

The business is unprofitable, but it has been growing at an impressive rate in recent years....…

Insiderhandel: Gen. Mgr., Precision Oncology verkauft Aktien von EXACT Sciences im Wert von 114.804$

Baranick, Brian - Vorstand - Tag der Transaktion: 2023-08-07...…